Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
At UCB, we’re continuously working to push the boundaries of science & technology. Gene therapy is rapidly progressing and we’re proud to be at the forefront of this exciting new era. Find out more about our ambition: https://t.co/chS2mQ824E #rdjobs
— UCB News (@ucb_news) 09.11.2021 -
UCB recently won an eco-design award at #PHARMAPACKEU. Find out how we’re delivering on a promise to make green our new normal in terms of packaging design thinking https://t.co/HBtZJuECKJ https://t.co/0sPDIyORQN
— UCB News (@ucb_news) 08.11.2021 -
For the first UCB sponsored Rare Disease Connect in Neurology meeting, taking place on November 10-12, we're joined by neuromuscular experts for a virtual collaboration to exchange knowledge and share expertise so we can make an impact in this field.
— UCB News (@ucb_news) 04.11.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
